Skip to content
Lower risk Drug recall · FDA · Published July 10, 2024

Endo Clonazepam Tablets Recalled Due to Labeling Error

Endo Pharmaceuticals recalls Clonazepam orally disintegrating tablets with incorrect strength labeling. Some cartons listed 0.125mg instead of 0.25mg, but tablets inside are correct. Consumers should check their product.

🇺🇸 FDA recall #D-0622-2024DrugEndo Pharmaceuticals ›
Take action

Contact the company

Recalling firmEndo Pharmaceuticals, Inc.1400 Atwater Dr · Malvern, PA 19355-8701
✎ GovInfoNow plain-language explainer

Endo Pharmaceuticals is recalling Clonazepam orally disintegrating tablets that were incorrectly labeled as 0.125mg instead of 0.25mg. This labeling error could lead to incorrect dosing if the product is used without checking the actual strength. Read more at govinfonow.com/recall/32590-endo-clonazepam-tablets-recalled-due-to-labeling-error.

Source Summary by GovInfoNow · govinfonow.com/recall/32590-endo-clonazepam-tablets-recalled-due-to-labeling-error · Updated September 23, 2026 · FDA enforcement record: FDA #D-0622-2024

Cite this page

“Endo Clonazepam Tablets Recalled Due to Labeling Error.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/32590-endo-clonazepam-tablets-recalled-due-to-labeling-error. Based on FDA recall #D-0622-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0622-2024%22&limit=1).

The FDA announced on July 10, 2024, that Endo Pharmaceuticals is recalling Clonazepam Orally Disintegrating Tablets due to a labeling error where some cartons were incorrectly labeled as 0.125 mg instead of the correct 0.25 mg strength. This Class I recall affects 8,139 cartons distributed nationwide.

How to tell if you have it

  • Brand: Endo Pharmaceuticals
  • Product: Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.125mg, 60 tablets per carton
  • NDC#: 49884-306-02
  • Lot code: 550147301
  • Expiration date: 08/31/2026
  • Distribution: Nationwide in the USA and Puerto Rico

The hazard

The hazard is a labeling error where some cartons were incorrectly labeled as 0.125 mg instead of 0.25 mg. The blister strips inside the product carton reflect the correct strength of 0.25 mg.

Context

GovInfoNow's records show Endo Pharmaceuticals has four other recalls on record since May 7, 2012. Other recent recalls of similar products include Annora Pharma Lacosamide Tablets Recall (June 4, 2026), Slate Run Recalls Eptifibatide Injection Due to Labeling Error (Feb. 12, 2026), and Inventia Chlorthalidone Recall (Sept. 3, 2026).

How to tell if you have this one

Check for the product name 'Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.125mg' on the carton. The actual tablets inside are 0.25mg, but the carton may incorrectly state 0.125mg.

  • Brand
    Endo Pharmaceuticals
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Label

    Look for the carton label stating 0.125mg instead of 0.25mg. The tablets inside are correctly labeled as 0.25mg.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide in the USA and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 14 months after the firm started it.

1. Firm started the recall: Jul 10, 202412. FDA classified it Class I: Jul 30, 202423. Published in FDA’s Enforcement Report: Aug 7, 202434. FDA terminated the recall: Sep 16, 2025420242025
  1. Firm started the recall
  2. FDA classified it Class I
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0622-2024 (July 10, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0622-2024 to see it in context.
  • Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA